734 related articles for article (PubMed ID: 31512514)
1. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.
Moosavi F; Giovannetti E; Saso L; Firuzi O
Crit Rev Clin Lab Sci; 2019 Dec; 56(8):533-566. PubMed ID: 31512514
[TBL] [Abstract][Full Text] [Related]
2. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
[TBL] [Abstract][Full Text] [Related]
3. MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
Kawakami H; Okamoto I
Gastric Cancer; 2016 Jul; 19(3):687-95. PubMed ID: 26690587
[TBL] [Abstract][Full Text] [Related]
4. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.
Bradley CA; Salto-Tellez M; Laurent-Puig P; Bardelli A; Rolfo C; Tabernero J; Khawaja HA; Lawler M; Johnston PG; Van Schaeybroeck S;
Nat Rev Clin Oncol; 2017 Sep; 14(9):562-576. PubMed ID: 28374784
[TBL] [Abstract][Full Text] [Related]
5. MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.
Salgia R
Mol Cancer Ther; 2017 Apr; 16(4):555-565. PubMed ID: 28373408
[TBL] [Abstract][Full Text] [Related]
6. Nonclinical evaluation of the serum pharmacodynamic biomarkers HGF and shed MET following dosing with the anti-MET monovalent monoclonal antibody onartuzumab.
Mai E; Zheng Z; Chen Y; Peng J; Severin C; Filvaroff E; Romero M; Mallet W; Kaur S; Gelzleichter T; Nijem I; Merchant M; Young JC
Mol Cancer Ther; 2014 Feb; 13(2):540-52. PubMed ID: 24258345
[TBL] [Abstract][Full Text] [Related]
7. Frequent hepatocyte growth factor overexpression and low frequency of c-Met gene amplification in human papillomavirus-negative tonsillar squamous cell carcinoma and their prognostic significances.
Kwon MJ; Kim DH; Park HR; Shin HS; Kwon JH; Lee DJ; Kim JH; Cho SJ; Nam ES
Hum Pathol; 2014 Jul; 45(7):1327-38. PubMed ID: 24810547
[TBL] [Abstract][Full Text] [Related]
8. Biomarker development in MET-targeted therapy.
Zhang Y; Du Z; Zhang M
Oncotarget; 2016 Jun; 7(24):37370-37389. PubMed ID: 27013592
[TBL] [Abstract][Full Text] [Related]
9. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
10. Clinical and prognostic value of the C-Met/HGF signaling pathway in cervical cancer.
Boromand N; Hasanzadeh M; ShahidSales S; Farazestanian M; Gharib M; Fiuji H; Behboodi N; Ghobadi N; Hassanian SM; Ferns GA; Avan A
J Cell Physiol; 2018 Jun; 233(6):4490-4496. PubMed ID: 29058790
[TBL] [Abstract][Full Text] [Related]
11. Aberrant
Al-Ghabkari A; Huang B; Park M
Cells; 2024 Jan; 13(3):. PubMed ID: 38334610
[TBL] [Abstract][Full Text] [Related]
12. Targeting the HGF/Met signaling pathway in cancer therapy.
Cecchi F; Rabe DC; Bottaro DP
Expert Opin Ther Targets; 2012 Jun; 16(6):553-72. PubMed ID: 22530990
[TBL] [Abstract][Full Text] [Related]
13. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
[TBL] [Abstract][Full Text] [Related]
14. Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder.
McNeil BK; Sorbellini M; Grubb RL; Apolo A; Cecchi F; Athauda G; Cohen B; Giubellino A; Simpson H; Agarwal PK; Coleman J; Getzenberg RH; Netto GJ; Shih J; Linehan WM; Pinto PA; Bottaro DP
J Transl Med; 2014 Oct; 12():199. PubMed ID: 25335552
[TBL] [Abstract][Full Text] [Related]
15. The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.
Maroun CR; Rowlands T
Pharmacol Ther; 2014 Jun; 142(3):316-38. PubMed ID: 24384534
[TBL] [Abstract][Full Text] [Related]
16. Targeting the hepatocyte growth factor-cMET axis in cancer therapy.
Blumenschein GR; Mills GB; Gonzalez-Angulo AM
J Clin Oncol; 2012 Sep; 30(26):3287-96. PubMed ID: 22869872
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of MET/HGF inhibitors in oncology.
Scagliotti GV; Novello S; von Pawel J
Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
[TBL] [Abstract][Full Text] [Related]
18. MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?
Gambella M; Palumbo A; Rocci A
Expert Rev Mol Diagn; 2015; 15(7):881-93. PubMed ID: 25967746
[TBL] [Abstract][Full Text] [Related]
19. Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells.
Qian LW; Mizumoto K; Inadome N; Nagai E; Sato N; Matsumoto K; Nakamura T; Tanaka M
Int J Cancer; 2003 May; 104(5):542-9. PubMed ID: 12594808
[TBL] [Abstract][Full Text] [Related]
20. Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash.
Hichert V; Scholl C; Steffens M; Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Oncotarget; 2017 May; 8(21):35193-35204. PubMed ID: 28456787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]